Drug discovery has always had a difficult timing problem. Scientists need to understand how molecules behave before they spend years and millions of dollars testing them in the lab, but the most accurate ways to study those molecules can be slow, expensive, and hard to use at scale. That is where Toru Shiozaki and QSimulate are trying to change the story.
Shiozaki is the co-founder and CEO of QSimulate, a company built around a clear scientific mission: make quantum-powered molecular modeling practical for real drug discovery work. Instead of treating quantum chemistry as something that belongs only in academic papers or specialized research groups, QSimulate is working to turn it into usable software for pharmaceutical teams that need better answers faster.
At the center of that work is QUELO, QSimulate’s lead optimization platform. It applies quantum mechanics to drug binding predictions, helping researchers study complex molecular interactions that can be difficult for traditional modeling tools to capture. For drug discovery teams, this matters because even tiny differences in molecular behavior can influence whether a compound becomes a useful medicine or gets dropped early in development.
Who is Toru Shiozaki
Toru Shiozaki is a quantum chemistry researcher turned startup founder. Before building QSimulate, he worked deeply in the world of academic chemistry, where researchers push the limits of what can be calculated, predicted, and understood at the molecular level.
That background matters because QSimulate is not built around a shallow technology trend. It comes from years of work in quantum chemistry, molecular simulation, and computational drug discovery. Shiozaki’s challenge has been to take ideas that were once too technical or too compute-heavy for everyday industry use and make them practical enough for researchers working on real drug programs.
QSimulate was founded in 2019 by Toru Shiozaki and Garnet Chan, another respected scientist in the field. Together, they built the company around the idea that quantum mechanics could do more than explain molecules in theory. It could help scientists make better decisions in drug discovery, materials science, and complex chemistry.
That shift from academic research to applied software is one of Shiozaki’s biggest achievements. Many powerful scientific ideas never leave the research lab because they are too slow, too expensive, or too difficult to operate. QSimulate is working on that adoption problem directly.
Why molecular modeling matters in drug discovery
Drug discovery depends on understanding how molecules interact with biological targets. A potential drug has to bind to the right protein, behave in the right way, avoid unwanted interactions, and remain stable enough to become a serious candidate. These questions are difficult because molecules are not static objects. They move, bend, respond to their environment, and interact through layers of physical forces.
Traditional molecular modeling tools have helped researchers for years, but they can struggle with certain types of chemistry. Some systems involve metal ions. Some involve covalent binders. Some drug molecules have strong charges or highly polarizable groups. Some targets, including RNA targets or complex protein environments, may require a deeper view of molecular behavior.
This is where quantum mechanics becomes valuable. Quantum mechanics describes the behavior of electrons and atoms at a fundamental level. In simple terms, it can help researchers look closer at the actual physics behind molecular interactions. The problem is that quantum mechanical simulations have historically required huge computing power, long runtimes, and specialized expertise.
That creates the gap QSimulate is trying to close. Drug discovery teams need tools that are both accurate and practical. A model that is accurate but takes too long may not fit into the pace of a research program. A model that is fast but misses important chemistry can lead teams in the wrong direction. Shiozaki’s work with QSimulate is focused on making that trade-off less painful.
How Toru Shiozaki turned quantum chemistry into QSimulate
The story behind QSimulate is not just about building another biotech software company. It is about translating serious science into something that can be used in day-to-day research.
In academia, quantum chemistry researchers often work at the edge of what computers can handle. They build better methods, improve algorithms, and study systems that classical approaches may not explain well. But industrial drug discovery has different needs. Pharma teams need reliable workflows, clear outputs, manageable costs, and tools that can support fast decisions.
Toru Shiozaki’s success with QSimulate comes from understanding both sides of that divide. He knows the scientific depth behind quantum mechanics, but he is also building for users who need speed, usability, and confidence in their predictions.
That is why QSimulate’s work is important. The company is not simply saying quantum mechanics is powerful. It is building software that lets researchers apply quantum mechanics to practical problems such as lead optimization, binding affinity prediction, and complex drug-target interactions.
What QSimulate is building
QSimulate develops quantum-powered simulation tools for drug discovery and chemistry. Its most visible platform is QUELO, which is designed for lead optimization. Lead optimization is the stage where scientists improve promising compounds so they become stronger, safer, and more drug-like.
At this stage, researchers often compare many related molecules. They want to know which changes improve binding, which ones weaken activity, and which compounds deserve more lab testing. A better modeling tool can help teams prioritize the right molecules earlier.
QUELO focuses on applying quantum mechanics directly to drug binding affinity predictions using free energy perturbation, often called FEP. This is important because binding affinity plays a major role in drug discovery. If a molecule binds strongly and selectively to a target, it may have a better chance of becoming a successful drug candidate.
QSimulate’s platform is especially relevant for difficult systems where standard approaches may be less reliable. These include charged ligands, metalloprotein targets, covalent binders, RNA targets, and molecules with strong polarization effects. In these cases, the details of electron behavior can matter a lot.
How QSimulate makes molecular modeling faster
Speed is one of the biggest reasons QSimulate stands out. Quantum mechanical simulation has traditionally been viewed as too slow for routine drug discovery workflows. If a calculation takes too long, researchers cannot use it often enough to guide active decision-making.
QSimulate has worked on this problem through a mix of scientific methods, software engineering, GPU computing, and cloud infrastructure. QUELO has been optimized to run on modern GPU-based systems, including cloud resources. The company has also used mixed-precision algorithms, which can help reduce computing cost while preserving the accuracy needed for useful results.
This matters because drug discovery is full of time-sensitive choices. Research teams may need to compare many compounds, adjust chemical designs, and decide which molecules should move forward. Faster simulation can help them explore more ideas without waiting too long for answers.
The real achievement is not just that QSimulate can run complex calculations. It is that the company is working to make those calculations fit into a practical research cycle. When molecular modeling becomes faster, it can move from being a special analysis step to a more routine part of discovery.
How QSimulate makes molecular modeling smarter
Faster software is useful, but speed alone is not enough. QSimulate’s bigger promise is smarter molecular insight.
In drug discovery, a wrong prediction can waste time and money. If researchers overvalue a weak molecule, they may spend resources on the wrong compound. If they miss a strong molecule, they may abandon something valuable too early. Better modeling can help reduce that uncertainty.
By using quantum mechanics, QSimulate aims to capture details that classical models can miss. These details may include polarization, charge movement, bond formation, metal interactions, and other molecular effects that are difficult to simplify. For challenging targets, this can be especially useful.
That is why Shiozaki’s work should be seen as more than a technical upgrade. It is part of a larger move toward more reliable computational drug discovery. Scientists do not just need faster predictions. They need predictions they can trust enough to guide expensive experiments.
Why QUELO matters for lead optimization
Lead optimization is one of the most demanding stages of drug discovery. At this point, teams are often working with molecules that already show promise, but still need improvement. A compound may bind well but have safety concerns. Another may be safer but less potent. Another may work in one setting but fail when the chemistry changes slightly.
QUELO is designed to support this stage by giving researchers a deeper view of how molecular changes affect binding. Instead of relying only on classical approximations, the platform brings quantum mechanical detail into the process.
This can be valuable for drug teams working on complex disease targets. It can also support programs where traditional tools struggle, such as covalent drugs, metal-binding compounds, charged molecules, and peptide-like molecules. QSimulate has also continued expanding QUELO’s capabilities, including work around larger molecules and peptide drugs.
For pharma teams, the benefit is not just scientific elegance. It is practical decision support. Better lead optimization can mean fewer dead ends, stronger prioritization, and more confidence before expensive lab work.
The role of cloud computing and GPUs
One reason QSimulate has been able to push quantum-powered simulation forward is its use of modern computing infrastructure. High performance computing, cloud systems, and GPU acceleration have changed what is possible for scientific software.
In the past, running heavy quantum mechanical simulations could require on-premises supercomputing resources and long timelines. That made it difficult for many organizations to use quantum methods regularly. By building around cloud-based high performance computing and GPU resources, QSimulate is helping make those methods more accessible.
This is a key part of Shiozaki’s achievement. Scientific software does not become useful just because the underlying theory is strong. It becomes useful when the full system works. That means the algorithms, hardware, user interface, workflow management, and cost structure all need to come together.
QSimulate’s work shows how modern drug discovery is becoming a blend of chemistry, software, physics, cloud infrastructure, and engineering. Shiozaki’s leadership sits at that intersection.
QSimulate’s place in the future of computational drug discovery
The future of drug discovery will likely involve more automation, stronger simulations, and closer links between artificial intelligence and physics-based modeling. AI can help generate ideas, detect patterns, and suggest new molecules. But those ideas still need to be tested against reality. Physics-based simulation can provide another layer of confidence.
This is where QSimulate may have an important role. Its tools can help researchers evaluate molecular behavior with more detail, especially in cases where conventional AI or classical modeling may not be enough.
QSimulate is also part of a broader movement in quantum chemistry and quantum computing. The company’s work connects today’s high performance classical computing with the long-term promise of quantum computing. Instead of waiting for fully mature quantum hardware, QSimulate is building useful quantum-inspired and quantum-mechanics-based tools that can run on today’s systems.
That practical mindset makes the company more interesting. It is not asking drug discovery teams to wait for the future. It is trying to bring deeper molecular modeling into workflows that researchers can use now.
Why Toru Shiozaki’s work stands out
Toru Shiozaki stands out because he is solving a difficult translation problem. He is taking advanced quantum chemistry and pushing it toward real-world use.
That is harder than it sounds. Drug discovery teams do not adopt new tools just because the science is impressive. They need tools that are reliable, fast enough, cost-aware, and understandable. They need software that works with their research goals, not against them.
QSimulate’s progress shows how powerful scientific ideas can become more useful when they are paired with strong engineering and a clear commercial focus. Shiozaki’s success is not only about founding a company. It is about helping quantum chemistry move closer to the people who can use it to discover better medicines.
In a field where speed and accuracy are often in tension, QSimulate is trying to make molecular modeling both faster and smarter. That is why Toru Shiozaki’s work matters. He is helping turn one of chemistry’s most complex toolsets into something drug discovery teams can apply with more confidence.
